Archivos de Medicina

Reporte de Caso

Concurrent Guillain-Barré syndrome and longitudinally extensive myelopathy secondary to SARS-CoV-2 infection. Case report

Maria Isabella BonillaArbeláez1, D’angelo Clavijo Salazar2, Juan Felipe Cruz López3,Daniela Duque Montoya4

Recibido para publicaci: 22-02-2024. Versi corregida: 29-04-2024. Aprobado para publicaci: 27-06-2024.

Modelo de citación: Bonilla Arbeláez M.I., Clavijo Salazar D, Cruz Lez J.F., Duque Montoya D,. Concurrent Guillain-Barré syndrome and longitudinally extensive myelopathy secondary to SARS-CoV-2 infection. Case report. Arch Med (Manizales). 2024;24(2). https://doi.org/10.30554/archmed.24.2.5044.2024

Abstract

Introduction: Severe acute respiratory syndrome caused by the severe acute respiratory virus SARS-CoV-2 may have a wide range of neurological manifestations. Guillain-Barré syndrome is a post-infectious acute polyneuropathy characterized by symmetrical and ascending flaccid paralysis, and is described as a complication of SARS-CoV-2 infection and other pathogens. Inflammatory myelopathies associated with the virus have also been described, among which transverse myelitis is the most frequent. Outstanding the autoinflammatory characteristics of both entities, concurrent presentation is possible. Case description: A 23-year-old male presented with pain and ascending acute weakness syndrome in the lower limbs with impossibility of urination and defecation over a 4-day course. The diagnosis of Guillain Barrè was made by electromyography, and thoracolumbar magnetic resonance imaging was performed, with findings of longitudinally extensive inflammatory myelopathy. An antibody test for SARS-CoV-2 was performed on the cerebrospinal fluid with a positive IgG result, considering neurological compromise due to the virus. Management was performed using plasmapheresis and methylprednisolone pulses, with a favorable response and hospital discharge. Discussion: The compromise of SARS-CoV-2 in the central and peripheral nervous systems is well known. Pathologies such as Guillain-Barrè syndrome have been widely reported and studied as a consequence of SARS-CoV-2 infection, and a variety of reports of longitudinally extensive inflammatory myelopathy associated with the pathogen have been published; however, the concurrence between both pathologies has been scarcely reported. Conclusions: It is necessary to consider a wide variety of atypical and even confluent presentations caused by infectious agents such as SARS-CoV-2 to achieve timely diagnosis and management that reduces morbidity and mortality in patients.

1 Estudiante de Medicina, Universidad de Caldas. https://orcid.org/0000-0001-6223-7685. isabellabonilla.ar@gmail.com 2 Médico General Universidad de Caldas. https://orcid.org/0000-0002-4416-3894?lang=en. 3 Médico General Universidad de Caldas. https://orcid.org/0000-0003-2207-0782. 4 Neuroga Universidad de La Sabana. https://orcid.org/0000-0003-2067-1322.

Keywords: Myelitis, Guillain-Barré syndrome, SARS-CoV-2, COVID-19.

Síndrome de Guillain-Barré concurrente y mielopatía longitudinal extensa secundaria a infecci por SARS-CoV-2. Reporte de un caso

Resumen

Introducción: El síndrome respiratorio agudo grave causado por el virus respiratorio agudo grave SARS-CoV-2 puede tener una amplia gama de manifestaciones neurolicas. El síndrome de Guillain-Barré es una polineuropatía aguda postinfecciosa caracterizada por parálisis flácida simétrica y ascendente, y se describe como una complicaci de la infecci por SARS-CoV-2 y otros patenos. También se han descrito mielopatías inflamatorias asociadas al virus, entre las que la mielitis transversa es la más frecuente. Destacando las características autoinflamatorias de ambas entidades, es posible la presentaci concurrente. Descripción del caso: Var de 23 as que presenta dolor y síndrome de debilidad aguda ascendente en miembros inferiores con imposibilidad de micci y defecaci de 4 días de evoluci. El diagntico de Guillain Barrè se realizmediante electromiografía, y se realizuna resonancia magnética toracolumbar, con hallazgos de mielopatía inflamatoria longitudinalmente extensa. Se realizuna prueba de anticuerpos para SARS-CoV-2 en el líquido cefalorraquídeo con un resultado positivo de IgG, considerando el compromiso neurolico debido al virus. Se realizmanejo con plasmaféresis y pulsos de metilprednisolona, con respuesta favorable y alta hospitalaria. Discusión: El compromiso del SARS-CoV-2 en los sistemas nerviosos central y periférico es bien conocido. Patologías como el síndrome de Guillain-Barrè han sido ampliamente reportadas y estudiadas como consecuencia de la infecci por SARS-CoV-2, y se han publicado diversos reportes de mielopatía inflamatoria longitudinalmente extensa asociada al pateno; sin embargo, la concurrencia entre ambas patologías ha sido escasamente reportada. Conclusiones: Es necesario considerar una amplia variedad de presentaciones atípicas e incluso confluentes causadas por agentes infecciosos como el SARS-CoV-2 para lograr un diagntico y manejo oportuno que reduzca la morbimortalidad de los pacientes.

Palabras clave: Mielitis, síndrome de Guillain-Barré, SARS-CoV-2, COVID-19.

Síndrome de Guillain-Barré concomitante e mielopatia longitudinal extensa secundária à infecção por SARS-CoV-2. Relatio de um caso

Resumo

Introdução: A síndrome respiratia aguda grave causada pelo vírus respiratio agudo grave SARS-CoV-2 pode apresentar uma ampla gama de manifestaçs neurolicas. A síndrome de Guillain-Barré é uma polineuropatia aguda p-infecciosa caracterizada por paralisia flácida simétrica e ascendente e é descrita como uma complicação da infecção por SARS-CoV-2 e outros patenos. Também foram descritas mielopatias inflamatias associadas ao vírus, entre as quais a mielite transversa é a mais frequente. Devido às características autoinflamatias de ambas as entidades, é possível uma apresentação simultânea. Descrição do caso: Um homem de 23 anos apresentou dor e síndrome de fraqueza aguda ascendente nos membros inferiores com impossibilidade de urinar e defecar em um período de 4 dias. O diagntico de Guillain Barrè foi feito por eletromiografia, e foi realizada uma ressonância magnética toracolombar, com achados de mielopatia inflamatia extensa longitudinalmente. Um teste de anticorpos para SARS-CoV-2 foi realizado no líquido cefalorraquidiano com um resultado IgG positivo, considerando o comprometimento neurolico devido ao vírus. O tratamento foi realizado com plasmaférese e pulsos de metilprednisolona, com uma resposta favorável e alta hospitalar. Discussão: O comprometimento do SARS-CoV-2 nos sistemas nervosos central e periférico é bem conhecido. Patologias como a síndrome de Guillain-Barrè foram amplamente relatadas e estudadas como consequência da infecção pelo SARS-CoV-2, e vários relatos de mielopatia inflamatria extensa longitudinalmente associada ao pateno foram publicados; no entanto, a simultaneidade entre as duas patologias foi pouco relatada. Conclusões:É necessário considerar uma ampla variedade de apresentaçs atípicas e até mesmo confluentes causadas por agentes infecciosos como o SARS-CoV-2 para obter um diagntico e um tratamento oportunos que reduzam a morbidade e a mortalidade dos pacientes.

Palavras-chave: Mielite, síndrome de Guillain-Barré, SARS-CoV-2, COVID-19.

Introduction

COVID-19 is an acute respiratory infection caused by the SARS-CoV-2 virus, declared a pandemic in 2020. The initial clinical symptoms were respiratory, with a broad spectrum ranging from mild upper respiratory symptoms to severe complications such as pneumonia, acute respiratory distress syndrome or shock, and organ failure.

Subsequently, a wide range of neurological signs and symptoms, such as anosmia, headache, vertigo, and others, are as severe as cerebrovascular attacks, acute encephalitis, and autoinflammatory syndromes [1] .

Guillain-Barré syndrome is an acute polyneuropathy characterized by symmetric and ascending flaccid paralysis, which has been described as a post-infectious complication of some pathogens, including SARS-CoV-2. Few cases of myelopathy associated with SarsCov-2 have been described, including some cases manifesting as transverse myelitis. [2,3] .

A case of concurrent Guillain Barré syndrome and longitudinally extensive transverse myelopathy secondary to SARS-CoV-2 infection is presented.

Case description

A 23-year-old male professional miner presented with pain, acute symmetric ascending weakness syndrome, loss of muscle strength, and impossibility of urination and defecation.

On physical examination, bilateral upper limb muscle strength was 5/5, and bilateral lower limb muscle strength was 0/5, with generalized areflexia without sensory alteration. The patient was febrile (38.9 °C) with a negative antigen test result for COVID-19. He was diagnosed with Guillain-Barrè Syndrome Hughes 4 and EGRIS 3 and was transferred to the intensive care unit. Treatment was performed with plasmapheresis, human immunoglobulin G (0.4/kg/day), and methylprednisolone pulses.

Due to early vesical incontinence, magnetic resonance imaging of the thoracolumbar spine was performed, which showed an alteration in the intensity of the spinal cord observed from the T2 level to the conus medullaris, which initiates in the anterior horns and then generalizes throughout the circumference of the spinal cord with significant thickening. These findings were consistent with longitudinally extensive transverse inflammatory myelopathy (Figure 1, 2, and 3).

Electromyography (EMG) described lumbosacral sensory-motor polyradiculoneuropathy of the axonal type. A cerebrospinal fluid (CSF) study showed slightly decreased glucose levels, increased protein levels, and neutrophilic pleocytosis (Table1). These results suggest a probable viral compromise, and we performed a study test for SARS-CoV-2 with a positive IgG result in the CSF, indicating neurological compromise as a consequence of infection by the pathogen.

Figure 3. Sequence T2

The patient presented a favorable response to treatment, was transferred to a general hospital, and was discharged. The response to physical therapy was satisfactory, and at 3 months, the patient walked without support and had adequate sphincter control.

Table 1. CSF EXAMINATION

Discussion

Viruses have an extensive repertoire of routes to infect, evade, and damage the infinity of organisms for which they have tropism. In humans, there are viruses with high specificity for the central nervous system (CNS). However, viruses with respiratory tropism, such as influenza, respiratory syncytial virus, metapneumovirus, and coronavirus, frequently generate manifestations of the CNS, reaching there through mechanisms such as the hematogenous route or through peripheral and olfactory nerves [4] , which are the pathways responsible for the arrival of SARS-CoV-2 in the central nervous system [5] .

Since the beginning of the pandemic, the compromise that SARS-CoV-2 could cause in the nervous system has been described, from common symptoms such as fatigue or anosmia [1,3] to more serious and infrequent manifestations in the CNS and peripheral nervous system [6,7]. It has been proposed that these manifestations are a consequence of factors such as direct viral infection, which leads to cell death (autophagy, apoptosis, or pyroptosis) or neuroinflammation (overactivation of cytokines and cells of the immune system) [8] .

This neuroinflammation, along with a dysregulated immune response, the production of autoantibodies, and antigenic mimicry, predisposes people to autoimmune presentations of viral diseases, including SARS-CoV-2 [9] and manifestations such as immune thrombocytopenic purpura, autoimmune hemolytic anemia, Kawasaki disease, Guillain Barrè syndrome, and transverse myelitis; the latter two are relevant in the present case [10] .

Guillain-Barré syndrome (GBS) has been widely reported and studied as a consequence of SARS-CoV-2 infection, and approximately 70% of GBS cases have a history of viral infection [11] .

The most recent meta-analyses and systematic reviews have shown variable data in the demographic and clinical presentation of patients with GBS secondary to COVID-19, which is a rare event in the pediatric population [12] , with a prevalence of 0.15% (15 cases per 100,000 inhabitants) in adults [13]. Men were more affected than women (68.5% vs. 31.5%) and were not significantly associated with previous comorbidities presented by patients. Recently, vaccination against SARS-CoV-2 has been implicated in the generation of GBS, with a prevalence of 3.09 cases per million inhabitants [14,15].

Clinically, the vast majority of patients have symptoms of COVID-19 at the time of the neurological condition; however, asymptomatic cases have also been reported, as well as cases that present negative RT-PCR results for SARSCoV-2 on admission, such as that observed in the present case [16] .

The initial manifestations of GBS are sensory symptoms alone or in combination with paraparesis or tetraparesis, with a high prevalence of generalized areflexia. Ascending weakness progressing to flaccid tetraparesis and extension or persistence of sensory symptoms are the most common clinical course [14] .

In a study of CSF, GBS classically presented an increase in proteins with a normal number of cells (albumin-cytological dissociation), which occurred between 56.6% and 71.2% of patients [13,14]. Our patient did not have this finding and presented with pleocytosis greater than 50 cells/

μl, which suggests a different pathology; in this

case, concomitant myelopathy.

In general, electrophysiological examination of patients with GBS shows polyradiculoneuropathy or sensorimotor polyneuropathy (as in the present case). EMG also reveals different patterns of GBS, among which acute inflammatory demyelinating polyneuropathy (AIDP) is the most common pattern in approximately 70-80% of cases [17].

Another pathology within the spectrum of autoimmune manifestations of SARS-CoV-2, which is closely related to the case presented, is acute myelopathy. These may be myelitis, defined as myelopathy due to inflammation within the spinal cord, demonstrated by CSF pleocytosis, an increased IgG index, and/ or gadolinium enhancement. Symptom progression should have peaked within 2–21 days [18].

The most common form of myelitis is transverse myelitis, which presents with bilateral signs and a well-defined sensory level. Udinal extensive myelopathy is another variant of transverse myelitis, a spinal cord injury that extends to at least three segments of the spinal cord, and its association with SARSCoV-2 is rarer [18]. This group of pathologies has a much lower incidence than GBS secondary to SARS-CoV-2 infection, mainly in case reports, case series, and systematic reviews [19 – 21].

Regarding the concurrence of pathologies, some cases of transverse myelitis and GBS have been reported after COVID-19 infection or vaccination [22,23]. However, while performing a non-systematic review of the literature on the concurrence between GBS and longitudinally extensive myelopathy secondary to SARSCoV-2 infection, only a single case was found with this set of conditions in an 11-year-old female patient [24], which is possibly the first case reported in an adult population.

Conclusions

Neurological compromise associated with SARS-CoV-2 infection is highly relevant owing to its significant morbidity and mortality. In case acute weakness is present in the socio-demographic context of the current pandemic, it is necessary to be aware of the wide variety of atypical presentations, and even confluent, related to SARS-CoV-2 infection to achieve timely diagnosis and management that reduces morbidity and mortality in patients who suffer from them. The coexistence of Guillain-Barré syndrome and infectious myelopathy is infrequent, and its clinical suspicion is based on adequate anamnesis and clinical neurological examination.

References

9.

11.

Immunology. 12.

13.

14. 15. 16.

18.

review. 19.

p. 7